8-K: Galectin Therapeutics Reports Q3 2025 Results, MASH Data

Galectin Therapeutics announced its Q3 2025 financial results and provided a business update, highlighting positive 18-month biomarker data for belapectin in MASH cirrhosis and ongoing FDA dialogue.

Summary

• Net loss applicable to common stockholders for Q3 2025 was $8.2 million, or ($0.13) per share, a decrease from $11.2 million, or ($0.18) per share, for Q3 2024.
• Research and development expenses for Q3 2025 were $2.6 million, significantly down from $7.6 million for Q3 2024, primarily due to the conclusion of the NAVIGATE clinical trial in Q1 2025.
• General and administrative expenses for Q3 2025 were $1.6 million, compared to $1.5 million for Q3 2024.
• Cash and cash equivalents stood at $11.5 million as of September 30, 2025.
• A new $10 million line of credit was secured on July 8, 2025, provided by the chairman of the board, to fund operations.
• Management believes the company has sufficient cash to fund planned operations and R&D activities through June 30, 2026.
• New 18-month biomarker analyses from the NAVIGATE trial for belapectin were presented at the 2025 AASLD Annual Meeting, supporting its antifibrotic and disease-modifying potential in compensated MASH cirrhosis and portal hypertension.
• Belapectin demonstrated consistent effects across key biomarkers including liver stiffness (LSM), ELF score, PRO-C3, YKL-40, and PRO-C4, indicating reduced fibrosis risk and improved liver function.
• Treatment with belapectin was associated with a reduced presence of clinically significant portal hypertension (CSPH) and a lower risk of hepatic decompensation at 18 months, based on validated Baveno VII criteria.
• The CSPH category for belapectin 2 mg/kg decreased from 33.3% to 25.9% (-22.2% change), while the no/low-risk category increased from 42.0% to 56.8% (35.2% change).
• Belapectin improved composite liver risk scores based on AGILE-4 assessment, with approximately 32% fewer subjects in the 2 mg/kg group experiencing a 20% worsening in AGILE-4 score.
• The NAVIGATE data package has been submitted to the FDA, with guidance on proposed next steps anticipated by year-end.

Sentiment

Score: 7

Explanation: The financial results show a reduced net loss and R&D expenses, coupled with a strengthened cash position. More importantly, the detailed positive clinical biomarker data for belapectin in MASH cirrhosis, including reductions in portal hypertension risk, are highly encouraging and represent significant progress for the lead drug candidate. The ongoing dialogue with the FDA and anticipated guidance by year-end are positive catalysts. However, the company still operates at a loss, has high liabilities, and relies on external partnerships for other programs, which tempers the overall sentiment.

Positives

• Net loss decreased to $8.2 million in Q3 2025 from $11.2 million in Q3 2024, indicating improved financial performance.
• Research and development expenses significantly decreased to $2.6 million in Q3 2025 due to the conclusion of the NAVIGATE trial, optimizing cost structure.
• Positive 18-month biomarker data from the NAVIGATE trial for belapectin demonstrate consistent antifibrotic and disease-modifying potential in MASH cirrhosis.
• Belapectin treatment was associated with a reduced presence of clinically significant portal hypertension (CSPH) and a lower risk of hepatic decompensation at 18 months, a critical outcome for MASH cirrhosis patients.
• A clear dose-response was observed in portal hypertension risk categories, reinforcing the biological rationale and potential efficacy of belapectin.
• Improvements in composite liver risk scores (AGILE-4) were observed with belapectin treatment, reflecting a meaningful reduction in disease progression.
• The company has sufficient cash to fund operations through June 30, 2026, bolstered by a new $10 million line of credit, providing financial stability for the near term.

Negatives

• The company continues to report a net loss of $8.2 million for Q3 2025, indicating ongoing operational expenses exceeding revenue.
• Total liabilities are significantly high at $136.4 million as of September 30, 2025, an increase from $120.6 million at December 31, 2024.
• Total stockholders deficit increased to $(125.3) million as of September 30, 2025, from $(104.8) million at December 31, 2024, reflecting accumulated losses.
• Advancement of additional clinical programs, such as cancer immunotherapy, is largely dependent on finding a suitable partner, indicating potential resource constraints for pipeline expansion.

Risks

• Full analysis of the NAVIGATE trial data may not ultimately produce positive data, despite initial encouraging biomarker results.
• Galectin may not be successful in developing effective treatments and/or obtaining the requisite regulatory approvals for the use of belapectin or any of its other drugs in development.
• The company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing, and control matters for its drug candidates.
• Current and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time-consuming and costly.
• Plans regarding development, approval, and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the company as determined by management and regulatory agencies.
• Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.
• Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations.

Future Outlook

Galectin Therapeutics anticipates receiving feedback and guidance from the FDA by year-end regarding the proposed next steps for the belapectin program. The company's focus remains on advancing dialogue with the FDA and exploring strategic opportunities to maximize the value of this promising program. Management believes current cash resources, including a new line of credit, are sufficient to fund operations and research and development activities through June 30, 2026.

Management Comments

• "The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan, ELF, and PRO-C3—all supporting belapectin’s durable antifibrotic activity and potential to slow disease progression in patients with compensated MASH cirrhosis." Joel Lewis, Chief Executive Officer and President.
• "Importantly, the concordant biomarker data across independent measures support the mechanistic rationale for Galectin-3 inhibition and highlight belapectin’s potential to favorably alter disease trajectory in patients with advanced, high-risk MASH cirrhosis." Khurram Jamil, M.D., Chief Medical Officer.
• "The data demonstrating reductions in Baveno VII defined portal hypertension risk categories are particularly encouraging, as they come from the sickest MASH cirrhosis patients studied to date. The results were consistent across both the overall and completer populations, with a clear dose-response observed, reinforcing the biological rationale." Khurram Jamil, M.D., Chief Medical Officer.

Industry Context

The MASH (Metabolic Dysfunction-Associated Steatohepatitis) with cirrhosis market represents a significant unmet medical need and a substantial drug development opportunity, as highlighted by Galectin Therapeutics. Belapectin's focus on inhibiting galectin-3 protein positions it within the growing field of targeted therapies for inflammatory and fibrotic diseases. The positive biomarker data, particularly regarding antifibrotic activity and reduction in portal hypertension risk, could differentiate belapectin in a competitive landscape where many MASH treatments are in development, but few have reached advanced stages for cirrhotic patients. The emphasis on non-invasive markers like FibroScan and ELF aligns with industry trends towards less invasive diagnostic and monitoring tools.

Comparison to Industry Standards

• The NAVIGATE trial enrolled one of the most advanced MASH cirrhosis patient populations among recent trials, as evidenced by the high proportion of subjects meeting clinically significant portal hypertension (CSPH) criteria at baseline. This indicates belapectin is being evaluated in a high-risk group, potentially demonstrating efficacy where other therapies might not.
• The use of validated Baveno VII criteria for portal hypertension and AGILE-4 for composite liver risk scores aligns with established industry standards for assessing liver disease progression and treatment efficacy, lending credibility to the reported improvements.
• The consistent, meaningful effects across multiple key biomarkers (FibroScan, ELF, PRO-C3, YKL-40, PRO-C4) for belapectin suggest a broad antifibrotic and disease-modifying impact, which is a strong indicator of potential clinical benefit compared to therapies with more limited biomarker responses.

Related Party Transactions

• A new $10 million line of credit was provided by the company's chairman of the board on July 8, 2025.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data and progress with the lead drug candidate, but also continued dilution risk from ongoing losses and potential future capital raises. The new line of credit from the chairman provides short-term financial stability.
• Patients (MASH cirrhosis): Hope for a potential new therapy that could slow disease progression and reduce portal hypertension, addressing a significant unmet medical need.
• Employees: Continued employment and focus on advancing the belapectin program.
• Creditors: The new line of credit and existing liabilities indicate ongoing financial obligations.

Next Steps

• Receive feedback and guidance from the FDA on proposed next steps for the belapectin program by year-end.
• Advance dialogue with the FDA regarding belapectin's development path.
• Explore strategic opportunities to maximize the value of the belapectin program.
• Seek a suitable partner for the advancement of additional clinical programs in cancer immunotherapy and other malignancies.

Key Dates

Recommendation

While the clinical data for belapectin in MASH cirrhosis are highly encouraging, demonstrating significant biomarker improvements and reduced portal hypertension risk, the company remains unprofitable with a substantial accumulated deficit and high liabilities. The reliance on FDA guidance and potential partnerships for future development, coupled with the inherent risks of clinical trials and drug approval, suggest a 'hold' position. Investors should await further clarity on the FDA's feedback and the company's strategic path forward, particularly regarding commercialization or partnership agreements, before making more aggressive investment decisions. The new line of credit provides some financial runway, but long-term funding remains a consideration.

Keywords

Galectin Therapeutics, GALT, MASH, cirrhosis, belapectin, NAVIGATE trial, FDA, biomarkers, fibrosis, portal hypertension, liver disease, clinical trial results, Q3 2025 earnings, biotechnology, pharmaceuticals